Lusutrombopag, also known as S-888711, is an orally bioavailable, small molecule thrombopoietin (TPO) receptor agonist being developed by Shionogi for chronic liver disease (CLD) patients with thrombocytopenia prior to elective invasive surgery. Lusutrombopag acts selectively on the human TPO receptor and activates signal transduction pathways that promote the proliferation and differentiation of bone marrow cells into megakaryocytes, thereby increasing platelet levels. In September 2015, lusutrombopag received its first global approval in Japan for the improvement of CLD-associated thrombocytopenia in patients scheduled to undergo elective invasive procedures.
Process for synthesizing lusutrombopag. Assignee Shanghai Wanquan Chemical Technology Co., Ltd., Peop. Rep. China. CN 106083759. (2016).
Fukui, Yuuki; Maegawa, Yusuke; Matsuura, Takaharu; Kurita, Takanori. Preparation of high-purity crystals of optically active compounds as thrombopoietin receptor agonists and their intermediates. Assignee Shionogi & Co., Ltd., Japan. WO 2015093586. (2015).
Takayama, Masami; Kurose, Noriyuki. Pharmaceutical composition containing optically active compound having thrombopoietin receptor agonist activity and intermediate thereof. Assignee Shionogi & Co., Ltd., Japan. WO 2009017098. (2009).
